{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-033064","form_type":"8-K","ticker":"AXSM","cik":"0001579428","company_name":"Axsome Therapeutics, Inc.","filed_at":"2025-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.059825+00:00","generated_at":"2026-05-25T10:22:53.540620+00:00","sec_items":["8.01","9.01"],"event_type":"litigation","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Axsome settles Sunosi patent litigation with Hikma; generic entry deferred to 2040","bullets":["Settlement with Hikma resolves patent litigation over Sunosi (solriamfetol) generic.","License for Hikma's generic Sunosi begins Sept 1, 2040 (with pediatric exclusivity) or March 1, 2040 (without).","Agreement subject to FTC/DOJ review; other patent litigation against other parties remains pending.","Axsome retains exclusive Sunosi rights until at least 2040, protecting key product revenue."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-033064","json":"https://secwatch.observer/filing/0000950170-25-033064.json","markdown":"https://secwatch.observer/filing/0000950170-25-033064.md","text":"https://secwatch.observer/filing/0000950170-25-033064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1579428/000095017025033064/0000950170-25-033064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1579428/000095017025033064/axsm-20250305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T10:22:53.540620+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}